| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 3,343 | 4,093 | 12,709* | 4,307 |
| General and administrative | 6,873 | 4,787 | 6,573* | 4,348 |
| Impairment of long-lived assets | - | - | 1,536* | - |
| Net gain on lease terminations | 1,944 | 633 | - | - |
| Loss from operations | -8,272 | -8,247 | -20,818* | -8,655 |
| Other income (expense), net | 451 | 688 | 992* | 906 |
| Net loss | -7,821 | -7,559 | -19,827* | -7,749 |
| Unrealized gain (loss) on marketable securities | - | - | -2* | - |
| Comprehensive loss | -7,821 | -7,559 | -19,829 | -7,749 |
| Basic EPS | -2.44 | -2.36 | -6.253 | -2.44 |
| Diluted EPS | -2.44 | -2.36 | -6.253 | -2.44 |
| Basic Average Shares | 3,208,744 | 3,205,866 | 3,170,967 | 3,178,710 |
| Diluted Average Shares | 3,208,744 | 3,205,866 | 3,170,967 | 3,178,710 |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)